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 3 
ABSTRACT  30 
 31 
WHO recently recommended linezolid should be prioritized in treatment regimens for 32 
drug-resistant tuberculosis (TB), but there are limited data on its pharmacokinetics (PK) 33 
in this population. We conducted an observational study to explore covariate effects on 34 
linezolid PK and to estimate the probability of PK/pharmacodynamic target attainment in 35 
South African patients with drug-resistant TB. Consecutive adults on linezolid-based 36 
regimens were recruited in Cape Town and underwent intensive PK sampling at steady-37 
state. Non-compartmental analysis was performed. Thirty participants were included: 15 38 
HIV-positive, 26 on the initial dose of 600 mg daily and 4 participants on 300 mg daily 39 
after dose reduction for linezolid-related toxicity. There was a negative correlation 40 
between body weight and exposure with 17.4% (95% confidence interval [CI], 0.1 to 41 
31.7) decrease in area under the concentration-time curve (AUC0-24) per 10 kg weight 42 
increment after adjustment for other covariates. Age was an independent predictor of 43 
trough concentration, with an estimated 43.4% (95% CI, 5.9 to 94.2) increase per 10-44 
year increment in age. The standard 600 mg dose achieved the efficacy target of free 45 
AUC/minimum inhibitory concentration (MIC) > 119 at wild type MIC values (≤ 0.5 46 
mg/L), but the probability of target attainment dropped to 61.5% (95% CI, 40.6 to 79.8) 47 
at the critical concentration of 1 mg/L. When dosed at 600 mg daily, trough 48 
concentrations were above the toxicity threshold of 2 mg/L in 57.7% (95% CI, 36.9 to 49 
76.6). This confirms the narrow therapeutic index of linezolid and alternative dosing 50 
strategies should be explored. 51 
  52 
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INTRODUCTION 53 
Drug-resistant TB is an ongoing global public health crisis; there were over half a million 54 
incident cases in 2017 with a case fatality ratio of approximately 40%, more than double 55 
that of drug-sensitive TB (1). New and repurposed drugs offer the hope of improved 56 
outcomes. One such agent, the oxazolidinone linezolid, has an impressive impact on 57 
treatment outcomes when added to multidrug regimens for multidrug- (MDR) and 58 
extensively drug-resistant (XDR) TB (2, 3). As a result, linezolid has been promoted to 59 
the list of priority ‘Group A medicines’ in the new WHO antituberculosis drug 60 
categorization (4) and is included in the experimental arms of multiple trials of novel 61 
regimens for drug-resistant TB. However, linezolid use is limited by dose- and duration-62 
related toxicity, and the optimal dosing strategy that balances efficacy and toxicity is 63 
unknown (5).  64 
 65 
The pharmacokinetics (PK) that underpins linezolid dosing is poorly defined in patients 66 
with TB, particularly at the most commonly used dose of 600 mg daily and amongst 67 
patients in sub-Saharan Africa where there is a high burden of HIV co-infection (6). 68 
Understanding linezolid PK is important for several reasons. First, PK variability of 69 
antituberculosis agents has been associated with unsuccessful treatment outcomes (7), 70 
which may also lead to treatment-emergent drug resistance where drug exposure falls 71 
below PK/pharmacodynamic (PD) targets (8). Population-specific factors, including 72 
genetic polymorphisms, may influence drug disposition and drug effects (9), and it is 73 
therefore essential to perform PK studies in diverse populations. Second, the 74 
myelosuppression and neuropathy associated with linezolid use, which is often 75 
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 5 
treatment-limiting (3), correlates with dose and trough concentrations (10). Linezolid 76 
toxicity may be increased amongst HIV-positive patients (11), which is especially 77 
relevant in sub-Saharan Africa where up to 60% of patients with drug-resistant TB are 78 
co-infected with HIV. Third, linezolid has limited selectivity for its ribosomal target in 79 
bacteria and binds to a homologous site in human mitochondria (12). Because of these 80 
shared linezolid targets in the pathogen and host, there is a narrow therapeutic window 81 
for which the optimal PK targets and dose have not been defined (5), but which is likely 82 
to be sensitive to PK variability. Finally, efficacy targets of antituberculosis drugs are 83 
influenced by minimum inhibitory concentration (MIC) distributions for M tuberculosis, 84 
but there are limited data on linezolid MICs in populations with drug-resistant TB (13). 85 
Applying observed linezolid drug exposures to putative PK/PD parameters for efficacy 86 
and toxicity may inform policy decisions around dose optimization until more robust 87 
clinical targets are defined.  88 
 89 
We aimed to describe the PK of linezolid in a population of patients with drug-resistant 90 
TB and a high burden of HIV in South Africa. We also explored the effect of key 91 
covariates on PK parameters and estimated the probability of PK/PD target attainment 92 
corrected for the M tuberculosis MIC distribution in this cohort. 93 
 94 
MATERIALS AND METHODS 95 
Study population 96 
We conducted a prospective observational PK/PD study of linezolid in adults treated 97 
with linezolid containing regimens for drug-resistant TB in South Africa. We enrolled 98 
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 6 
participants from two studies: an observational cohort study of patients with pre-XDR 99 
and XDR-TB on bedaquiline containing regimens (PROBeX); and from the intervention 100 
arm of an open label clinical trial examining a shortened injection-free regimen for MDR-101 
TB (NExT; ClinicalTrials.gov NCT02454205). The initial dose of linezolid used in both 102 
studies was 600 mg daily but was reduced to 300 mg daily in the event of toxicity at the 103 
discretion of local clinicians or trial staff. Consecutive participants enrolled in the 104 
intervention arm of the NExT trial and those receiving linezolid as part of standard of 105 
care in PROBeX were approached to provide informed consent for intensive PK 106 
sampling. Eligible participants were over the age of 18 years, had a known HIV test 107 
result, and had culture-confirmed drug-resistant TB. Most of the participants in PROBeX 108 
were inpatients at the time of the intensive sampling visit, and all of the NExT 109 
participants attended as outpatients.  110 
 111 
The study was approved by the ethics committees at the University of Cape Town (refs 112 
264/2015 and 920/2015) and Albert Einstein College of Medicine (ref 2014-4348). 113 
 114 
Data collection 115 
Participants underwent PK sampling on a single occasion pre-dose and at 1, 2, 3, 4, 5, 116 
6, and 24 hours after a standardized meal and observed linezolid administration. Some 117 
participants in the PROBeX cohort had an additional sample taken at 8 and 48 hours as 118 
part of other study procedures. The sampling visit was scheduled at Month 2 of linezolid 119 
treatment and was thus performed at steady-state. Blood draws were done through a 120 
peripheral intravenous catheter placed for the duration of the first day of the visit. 121 
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Samples were collected into 10 mL K3EDTA Vacutainer tubes and centrifuged (1,500 x 122 
g for 10 minutes) within 30 minutes of collection. At least 1.5 mL of plasma was pipetted 123 
into polypropylene tubes and immediately frozen at -80°C. Linezolid concentrations 124 
were measured in Division of Clinical Pharmacology at the University of Cape Town 125 
using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) 126 
assay. Using a deuterated internal standard, the LC-MS/MS method for linezolid was 127 
validated over a calibration range of 0.100 mg/L to 30 mg/L. Over the period of sample 128 
analysis (n = 8 batches), a mean percentage accuracy of 98.8 was achieved, with a 129 
mean precision of 5.93 (%CV).   130 
 131 
Because the 24-hour dose was unobserved and may have been administered prior to 132 
the 24-hour sample, concentration-time profiles were inspected for each subject to 133 
compare pre-dose and 24-hour concentrations. The 24-hour concentration was 134 
considered highly unlikely to represent the true trough value where it exceeded the pre-135 
dose concentration and was > 50% of the concentration at the prior sampling time point 136 
(6- or 8-hours). This was based on the published elimination half-life of linezolid of ~6 137 
hours (14, 15), and the assumption that the 24-hour concentration would therefore fall 138 
below the 6- or 8-hour concentration in the absence of additional dosing. In these 139 
cases, the 24-hour concentration was imputed from either the pre-dose concentration or 140 
the mean of the pre-dose and 48-hour concentrations where available (and when the 141 
48-hour concentration satisfied the same criteria in relation to the pre-dose value). Pre-142 
dose concentrations reported as below the limit of assay quantification (BLQ) were 143 
imputed as 50% of the lower limit of detection (i.e. 0.05 mg/L), unless there was a 144 
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history of missed doses prior to the PK visit, in which cases BLQ was replaced by a 145 
value of ‘0.’  146 
 147 
Demographic and clinical data were collected from participants at the time of the PK 148 
visit, as well as from other visits as part of the parent studies. Data included HIV status, 149 
linezolid dose and duration, concomitant antituberculosis drugs and antiretrovirals, and 150 
most recent serum creatinine. Timing of administration of linezolid and other 151 
antituberculosis drugs was recorded.  152 
 153 
Linezolid MIC testing was performed on M tuberculosis isolates collected at the time of  154 
entry into the parent studies using the mycobacterial growth indicator tube (MGIT) 155 
system and continuous growth monitoring with Epicenter software (16). Dilutions ranged 156 
from 0.25 mg/L to 2 mg/L based on the epidemiological cut off (ECOFF) value of 0.5 157 
mg/L (17) and the critical concentration of 1 mg/L (13). 158 
 159 
Analysis 160 
Demographic and clinical characteristics were summarized and compared using the 161 
Wilcoxon rank-sum test for continuous variables and 2 test for dichotomous variables. 162 
Non-compartmental analysis was used to estimate linezolid PK parameters from 163 
observed concentrations. The area under the concentration-time curve over the 24-hour 164 
dosing period (AUC0-24) was computed using the cubic splines method. The trough 165 
concentration was defined as the plasma concentration 24 hours after observed intake 166 
(actual or imputed as described above). The elimination rate constant (ke) was 167 
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 9 
assessed by linear regression analysis of the last three concentrations in the terminal 168 
log-linear period. The apparent clearance of the drug (CL/F) and the volume of 169 
distribution after oral administration (Vd/F) were calculated using standard equations.  170 
 171 
We performed linear regression to explore associations between clinically relevant 172 
covariates and linezolid exposure. AUC0-24 and trough concentrations were log-173 
transformed and regressed versus weight, age, sex, ethnicity, HIV status, estimated 174 
creatine clearance (calculated using the Cockcroft-Gault formula), and concurrent use 175 
of ritonavir-boosted lopinavir. This latter parameter was included to explore a possible 176 
drug-drug interaction with linezolid, which may be a substrate of the drug transporter P-177 
glycoprotein (18) that is inhibited by HIV protease inhibitors. Parameters with a P value 178 
< 0.5 were retained in the multivariable model, using a backward stepwise approach. 179 
Regression coefficients were exponentiated and transformed into a value reflecting 180 
percentage change ((e - 1)∙100) for ease of interpretation. 181 
 182 
The PK/PD target for efficacy was defined as free AUC0-24/MIC (fAUC/MIC) of 119, 183 
based on findings from a hollow fiber infection model (19). Protein binding of 30% was 184 
used to calculate fAUC (15). The PK/PD parameter for toxicity was a trough 185 
concentration of 2 mg/L, based on clinical data showing increased mitochondrial and 186 
clinical linezolid toxicity above this threshold (10). The probability of target attainment 187 
was calculated as the proportion of subjects with PK exposures above the efficacy and 188 
toxicity targets. Probability distributions were constructed using kernel densities of PK 189 
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parameters, stratified by MIC. Statistical analysis, including non-compartmental 190 
analysis, was performed using Stata version 14.2 (StataCorp). 191 
 192 
RESULTS 193 
Study population 194 
Thirty-eight participants were screened between June 2016 and April 2018, and 30 195 
underwent intensive PK sampling. Reasons for exclusion were discontinuation of 196 
linezolid prior to the sampling visit (n = 4), withdrawal of consent (n = 2), loss to follow 197 
up (n = 1), and failed intravenous access (n = 1). The demographic and clinical 198 
characteristics at the time of linezolid sampling are summarized in Table 1. All 199 
participants were ambulant at the time of evaluation, including the 21 participants 200 
hospitalised for the PROBeX study. Five participants were on lopinavir-ritonavir-based 201 
ART. Four participants were on 300 mg daily after undergoing dose reduction for 202 
suspected linezolid-related toxicity, one of whom was switched to the 300 mg dose on 203 
the day of the study visit and therefore was not at steady state. 204 
 205 
PK parameters 206 
Trough concentrations were imputed for 6 participants due to extreme outlying results 207 
from presumed unobserved dosing prior to the 24-hour sample. The pre-dose 208 
concentration was BLQ in 4 participants. The full dataset showing original and imputed 209 
linezolid concentrations is available in the supplementary material (Table S1), along 210 
with the respective concentration-time profiles for each subject (Figures S1a and S1b).   211 
 212 
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 11 
As shown in Figure 1, concentration-time profiles demonstrated high inter-individual 213 
variations in plasma concentrations, with an overall coefficient of variation (%CV) of 214 
40.1%.  There was a rapid attainment of peak concentrations, which was similar for both 215 
doses, but concentrations at early time points appeared to be highly variable. Table 2 216 
summarizes the estimated PK parameters from observed linezolid concentrations, 217 
disaggregated by linezolid dose. Clearance was significantly lower amongst subjects 218 
who had undergone dose reduction to 300 mg daily (1.8 L/h (IQR 1.7 to 21) versus 3.1 219 
L/h (IQR 2.4 to 4.3) in those remaining on 600 mg daily; P = 0.012), which resulted in a 220 
longer half-life in the 300 mg group. There was a linear correlation between linezolid 221 
trough concentrations and AUC0-24; ρ
 = 0.5, P = 0.005 (Figure S2). 222 
 223 
Covariate effects on PK parameters 224 
Linear regression only included participants receiving the 600 mg dose (n = 26) since 225 
the sample size of those receiving 300 mg (n = 4) was too small to allow for a 226 
meaningful evaluation at that dose. There was no association between HIV infection or 227 
the use of lopinavir-ritonavir and linezolid exposure on univariable or multivariable 228 
analysis. The final multivariable model described 33% of the variability associated with 229 
AUC0-24 (Table 3). After adjustment for age, sex, race, and HIV status, there was a 230 
negative correlation between body weight and linezolid exposure, with an estimated 231 
17.4% (95% CI, 0.1 to 31.7) decrease in AUC0-24 per 10 kg increment. Age was 232 
significantly associated with higher trough concentrations, and remained an  233 
independent predictor on multivariable analysis, with an estimated 43.4% (95% CI, 5.9 234 
to 94.2) increase in trough concentrations per 10-year increment in age (Table 4).  235 
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 236 
Probability of PK/PD target attainment 237 
MIC results were available for the baseline isolates of 16 participants. The median MIC 238 
was 0.5 mg/L, range 0.25 to 0.5 mg/L. At this MIC distribution, the probability of efficacy 239 
target attainment, defined as a fAUC/MIC of 119, was 100% (95% CI, 87 to 100) for the 240 
600 mg dose of linezolid. This finding was consistent after performing a sensitivity 241 
analysis using the original outlier trough concentrations. The fAUC distributions across 242 
four MIC strata are shown in Figure 2. Although the PK/PD target would be achieved in 243 
almost all subjects at the ECOFF value of 0.5 mg/L, only 61.5% (95% CI, 40.6 to 79.8) 244 
of patients would exceed an fAUC/MIC of 119 at the critical concentration of 1.0 mg/L 245 
(13). Trough concentrations exceeded the toxicity threshold of 2 mg/L in 57.7% (95% 246 
CI, 36.9 to 76.6) of those on 600 mg daily, and in 75% (95% CI, 19.4 to 99.4)  of those 247 
who had undergone dose reduction to 300 mg daily. In a sensitivity analysis the 248 
proportions exceeding the toxicity threshold were similar when original trough 249 
concentration data were used: 67.7% (95% CI, 47.1 to 82.7) versus  60% (95% CI, 40.6 250 
to 77.3) with imputed data at all doses. 251 
 252 
DISCUSSION 253 
We characterized the PK of linezolid in 30 South African participants with drug-resistant 254 
TB and a high prevalence of HIV co-infection. We showed that age and weight were the 255 
most important predictors of linezolid exposure. A major finding was that the standard 256 
600 mg dose resulted in exposures that reached efficacy targets, but a substantial 257 
proportion of individuals were exposed to concentrations exceeding the known toxicity 258 
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threshold. Of concern, at the critical concentration (1 mg/mL) efficacy targets would only 259 
be achieved in 61.5%, which has implications for the programmatic use of linezolid as 260 
resistance is expected to increase with more widespread use. 261 
 262 
Despite its growing importance as a key drug for the treatment of drug-resistant TB, the 263 
optimal dose and duration of linezolid for this indication is unknown. There are very 264 
limited published PK data for linezolid in TB patients to help inform an effective dosing 265 
strategy that minimizes both mitochondrial toxicity and the emergence of resistance. 266 
Eight clinical studies reporting linezolid PK in TB treatment were identified in a recent 267 
systematic review (6) but these studies had four different dosing strategies and mostly 268 
did sparse sampling PK schedules, limiting their generalizability. Only two studies (n = 269 
48) (2, 20) have evaluated linezolid PK at the standard dose for TB of 600 mg daily; all 270 
were HIV-negative and full PK profiles were only done in 10 participants (20). Our study 271 
provides a comprehensive description of plasma linezolid concentrations at the 272 
recommended dose of 600 mg daily for drug-resistant TB and is the first to include HIV-273 
positive patients. 274 
 275 
We found high interindividual PK variability, as has been observed in patients with 276 
Gram-positive infections (21), particularly at early sampling time points, suggesting 277 
variable absorption delay. Most of the PK variability was unexplained by the covariates 278 
included in the regression model and was likely due to stochastic effects; however, this 279 
needs to be quantified with formal population PK modelling, possibly incorporating an 280 
absorption lag phase. Linezolid clearance was lower amongst participants who 281 
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underwent dose reduction to 300 mg, which could be explained by channeling bias, as 282 
patients with lower linezolid clearance would have higher exposure and be more 283 
susceptible to toxicity, necessitating a dose reduction. Although the sample size was 284 
small, the median trough concentration with the reduced 300 mg daily doses exceeded 285 
the toxicity threshold of 2 mg/L in three of four participants. This finding emphasizes the 286 
need for toxicity monitoring with linezolid therapy, even after dose reduction for adverse 287 
events.  288 
 289 
The median trough concentrations were higher in our cohort compared with the two 290 
previous studies of linezolid 600 mg daily in TB therapy (2, 20). Although there is 291 
substantial interstudy heterogeneity in linezolid PK parameters (6), our finding may 292 
suggest a longer terminal half-life with an attendant increased risk of toxicity in our 293 
population. A small clinical study found a trend towards an association between HIV 294 
infection and higher rates of linezolid toxicity (11); if this association is confirmed in 295 
larger prospective cohorts, it is likely to be explained by predisposition to the high 296 
prevalence of neuropathy and limited bone marrow reserve in people with advanced 297 
HIV disease rather than higher linezolid exposure, which we did not find. We explored 298 
the potential PK drug-drug interaction between linezolid and lopinavir-ritonavir as an 299 
additional contributing factor to increased linezolid exposures and toxicity in HIV. An 300 
association between the use of lopinavir-ritonavir and linezolid trough concentrations 301 
was not detected in our cohort, but this needs confirmation with a larger sample size.  302 
 303 
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In a previous study, increasing age accounted for a small reduction (2%) in linezolid 304 
clearance in patients with Gram-positive infection (22), but did not contribute to the 305 
development of a population PK model of linezolid in TB (23), and did not influence 306 
linezolid exposures in a study of healthy volunteers (24). By contrast, we showed a 307 
significant correlation between increasing age and linezolid trough concentrations, 308 
where every 10-year increment in age was associated with 43% higher trough 309 
concentrations; this finding needs to be validated in similar populations. We also found 310 
a significant association between weight and lower linezolid exposure in the 311 
multivariable model, an association previously reported (25). These observations have 312 
implications for dose selection and could inform therapeutic drug monitoring (TDM) 313 
strategies for linezolid; for example, by targeting TDM to older patients and those with 314 
lower weights to prevent toxicity.  315 
 316 
PK targets for efficacy have not been established for linezolid in TB treatment. Although 317 
Cmax/MIC (26) and trough/MIC (27) have been associated with bacterial killing using ex 318 
vivo and in vitro models, the PK/PD index most consistently linked to linezolid activity in 319 
M tuberculosis is the fAUC0-24/MIC ratio (19, 28, 29). A hollow-fiber infection model, 320 
which recapitulates human drug exposure, showed that optimal mycobacterial kill was 321 
achieved at a fAUC0-24/MIC ratio of 119 (19); this was used as the PK/PD parameter in 322 
a recent simulation of published linezolid PK data to determine the probability of efficacy 323 
target attainment at wild type MIC values (6). Using data from 10 patients with full PK 324 
profiles, with an estimated median AUC0-24 of 98.6 mg.h/L (23), those simulations 325 
predicted that 45% would fail to achieve the target at a daily dose of 600 mg. 326 
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Reassuringly, in our participants linezolid exposures were higher (median AUC0-24 200.2 327 
mg.h/L), translating into probability of target attainment of 100% across the MIC 328 
distribution in baseline isolates and 96% at the population wild type MIC cut-off of 0.5 329 
mg/kg, supporting the efficacy of the 600 mg daily dose. However, linezolid exposures 330 
did not exceed the putative efficacy threshold at the critical concentration of 1 mg/L in 331 
38% of our subjects. With the expanding use of linezolid for TB treatment it will be 332 
essential to monitor for evidence of ‘MIC creep’ in the population.  333 
 334 
Unlike the PK/PD parameter for efficacy, the linezolid toxicity threshold is relatively well-335 
defined as a trough concentration of 2 mg/L, supported by clinical evidence (10) as well 336 
as data from pre-clinical models showing that mitochondrial toxicity is related to trough 337 
concentrations (27). Although a 600 mg daily dose was likely to reach the efficacy target 338 
in our cohort, almost 58% also exceeded this threshold concentration for linezolid 339 
toxicity,  clearly illustrating the narrow therapeutic window of linezolid. In murine models, 340 
linezolid’s sterilizing ability is dose-related and can occur within 2 months of effective 341 
combination therapy (30, 31). In TB patients, neurological toxicity tends occur late, 342 
usually after 2 months of therapy (32). Based on these observations, an appealing 343 
dosing strategy could be to provide higher linezolid doses (1,200 mg daily) for an initial 344 
‘intensive phase’ of treatment, followed by either discontinuation, dose reduction, or 345 
intermittent dosing (33) that allows longer periods within the PK safety window. This 346 
strategy needs to be evaluated in prospective studies. 347 
 348 
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We acknowledge a number of limitations of our study, including the inability of non-349 
compartmental analysis to assess intra-individual PK variability, evaluation at only a 350 
single time point during treatment, an incomplete PK profile and non-steady state 351 
dosing for one participant each, and small numbers of participants receiving the 352 
reduced 300 mg dose. Importantly, we had to impute the trough concentrations for six 353 
participants due to extremely high values after suspected unobserved dosing prior to 354 
the 24-hour sample. If anything, inclusion of the original data would have biased the 355 
results towards higher trough concentrations and overall exposures. Thus, our reported 356 
findings may represent a conservative estimate of both efficacy and toxicity target 357 
attainment.  358 
 359 
In conclusion, we found substantial variability in linezolid drug concentrations in this 360 
cohort of patients with drug-resistant TB and a high prevalence of HIV infection. Much of 361 
this variability was unexplained, but age and weight were identified as predictors of 362 
trough concentrations and exposure, respectively. The standard 600 mg dose is likely to 363 
achieve efficacy targets for M tuberculosis isolates with linezolid wild type MICs. The 364 
clinical impact of this needs to be evaluated by linking linezolid PK to toxicity and 365 
efficacy endpoints. In the meantime, the expanding use of linezolid 600 mg daily for 366 
drug-resistant TB should be supported by programmatic surveillance of MICs and 367 
adverse events. Alternative dosing strategies and TDM should be explored to optimize 368 
the use of this important but toxic antituberculosis agent. 369 
 370 
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FIGURE LEGENDS 512 
 513 
Figure 1. Plasma free concentration-time data for 30 subjects on linezolid.  514 
The grey lines represent concentration-time profiles for individual subjects; green dotted 515 
line is the median for the 600 mg dose, blue dotted line is the median for the 300 mg 516 
dose. The horizontal red line on the y-axis represents the critical concentration of 517 
linezolid of M tuberculosis (1 mg/L). 518 
 519 
Figure 2. Probability density distributions for efficacy target attainment of 520 
linezolid for subjects on 600 mg daily. 521 
The solid vertical line on the x-axis represents the experimentally-derived efficacy target 522 
fAUC/MIC0-24 of 119. Note the log-scale on the x-axis. 523 
 524 
 525 
  526 
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TABLES 527 
 528 
Table 1. Demographic and clinical characteristics 529 
Variable N = 30 
Age, years 33 (27 – 44) 
Male sex 19 (63) 
Weight, kg 58.5 (49.8 – 67.6) 
Height, cm 164.5 (158 – 172) 
BMI, kg/m2 20.2 (18.1 – 25.5) 
Ethnicity 
Black 
Mixed 
 
14 (47) 
16 (53) 
Baseline resistance pattern 
MDR-TB 
XDR-TB 
 
9 (30) 
21 (60) 
HIV positive 
Current ART 
Current LPV/r 
15 (50) 
15 (100) 
5 (33) 
Creatinine, µmol/L 65 (53 – 71) 
Creatinine clearance, mL/min 116 (103 – 139) 
Duration on linezolid, days 59 (55 – 63), range (20 – 95) 
Daily dose 600 mg 26 (87) 
Dose, mg/kg 10.0 (8.3 – 11.5) 
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Data are median (IQR) or n (%). BMI, body mass index; ART, antiretroviral therapy; 530 
LPV/r, lopinavir-ritonavir. 531 
 532 
  533 
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Table 2. PK parameters 534 
Variable 600 mg 
(n = 26) 
300 mg 
(n = 4) 
Overall 
(n = 30) 
AUC0-24, mg∙h/L 
CV (%) 
200.2 (139.9 – 250.8) 
41.0 
165.8 (144.3 – 173.7) 
13.2 
178.9 (139.9 – 244.4) 
40.1 
Ke, h
-1 0.08 (0.07 - 0.11) 0.06 (0.06 – 0.09) 0.08 (0.07 – 0.11) 
T1/2, h 8.4 (6.3 – 9.8) 11.2 (8.6 – 11.9) 9.1 (6.3 – 10.3) 
Cmax, mg/L 14.6 (13.4 – 18.1) 8.4 (8.2 – 9.8) 14.0 (12.0 – 17.4) 
Tmax, h 3 (2 – 4) 2 (2 – 2) 3 (2 – 4) 
Trough, mg/L 3.4 (1.6 – 5.1) 
74.0 
2.4 (1.9 – 2.6) 
47.7 
2.9 (1.6 – 5.1) 
73.0 
CL/F, L/h* 
CV (%) 
3.1 (2.4 – 4.3) 
69.4 
1.8 (1.7 – 2.1) 
14.7 
2.6 (2.3– 4.1) 
71.4 
Vd/F, L
# 37.8 (24.4 – 54.8) 31.2 (21.6 – 35.9) 36.8 (25.4 – 45.3) 
Data are median (IQR). AUC0-24, area under the 24-hour concentration-time curve; Ke, 535 
elimination constant; T1/2, elimination half-life; Cmax, maximum concentration; Tmax, time 536 
of maximum concentration; Trough, 24-hour/pre-dose concentration; CL/F. clearance; 537 
Vd, volume of distribution; CV, coefficient of variation. *Dose/AUC, 
#CL/ke 538 
 539 
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Table 3. Univariable and multivariable linear regression models describing 541 
associations between the AUC0-24 for linezolid 600 mg daily and selected 542 
covariates. 543 
 Univariable Multivariable 
n = 26 AUC0-24 change*  
% (95% CI) 
P value 
AUC0-24 change*  
% (95% CI) 
P value 
Male sex -13.0 (-42.2 – 
30.9) 
0.488 -24.9 (-49.9 – 
12.6) 
0.156 
Age 
Per 10-year 
increase 
7.3 (-11.2 – 29.6) 0.452 18.7 (-2.1 – 43.9) 0.078 
Black African 9.6 (-26.5 – 63.5) 0.641 -17.3 (-33.1 – 2.2) 0.075 
Weight 
Per 10 kg increase 
-11.9 (-25.8 – 4.4) 0.136 -17.4 (-0.1 – -31.7) 0.049 
BMI, kg/m2 -1.6 (-5.9 – 2.9) 0.458  
HIV positive -14.3 (-42.3 – 
27.5) 
0.430 -27.2 (-53.5 – 
13.8) 
0.154 
Current LPV/r -18.9 (-50.9 – 
43.1) 
0.399  
Dose, mg/kg 7.5 (-2.3 – 18.2) 0.132  
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Creatinine 
clearance, mL/min 
-0.5 (-1.1 – 0.1) 0.108  
*Percentage change in AUC0-24 calculated as [(e
 - 1)∙100]. BMI, body mass index. BMI, 544 
body mass index; LPV/r, lopinavir-ritonavir. Variables were excluded from the final 545 
multivariable model due to collinearity or as a result of backward elimination after 546 
exceeding the P-value inclusion threshold. 547 
 548 
  549 
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Table 4. Univariable and multivariable linear regression models describing 550 
associations between linezolid 600 mg daily trough concentrations and selected 551 
covariates. 552 
 Univariable Multivariable 
n = 26 Trough change  
% (95% CI) 
P 
value 
Trough change  
% (95% CI) 
P 
value 
Male sex 10.7 (-41.5 – 109.9) 0.744  
Age 
Per 10-year increase 
37.4 (5.4 – 79.2) 0.021 43.4 (5.9 – 94.2) 0.022 
Black African 26.1 (-31.9 – 133.3) 0.445 -13.8 (-37.4 – 18.7) 0.346 
Weight 
Per 10 kg increase 
9.3 (-17.1 – 43.9) 0.514  
BMI, kg/m2 1.0 (-5.8 – 8.4) 0.770  
HIV positive 16.1 (-37.7 – 116.2) 0.625 -27.9 (-66.9 – 56.4) 0.389 
Current LPV/r 11.5 (-49.4 – 145.5) 0.778 37.1 (-42.9 – 229.6) 0.463 
Dose, mg/kg -4.3 (-17.9 – 11.6) 0.560  
Creatinine clearance, 
mL/min  
-0.2 (-1.2 – 0.8) 0.650   
*Percentage change in trough concentrations calculated as [(e
 - 1)∙100]. BMI, body 553 
mass index; LPV/r, lopinavir-ritonavir. Variables were excluded from the final 554 
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multivariable model due to collinearity or as a result of backward elimination after 555 
exceeding the P-value inclusion threshold. 556 
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Figure 1. Plasma free concentration-time data for 30 subjects on linezolid.  
The grey lines represent concentration-time profiles for individual subjects; green dotted line is the median for the 600 mg 
dose, blue dotted line is the median for the 300 mg dose. The horizontal red line on the y-axis represents the critical 
concentration of linezolid of M tuberculosis (1 mg/L). 
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Figure 2. Probability density distributions for efficacy target attainment of linezolid for subjects on 
600 mg daily. 
The solid vertical line on the x-axis represents the experimentally-derived efficacy target fAUC/MIC0-24 of 119. Note 
the log-scale on the x-axis. 
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